We thank Dr. Bravaccini et al. for their thoughtful comments on our work [
[1]
] on the evolution of HER2-low expression between early and advanced breast cancer.
The authors highlight some important challenges existing in the diagnosis of HER2-low
breast cancer, an entity still under definition.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Evolution of low HER2 expression between early and advanced-stage breast cancer.Eur J Cancer. Mar. 2022; 163: 35-43https://doi.org/10.1016/j.ejca.2021.12.022
- LBA1 - unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial.Ann Oncol. 2022; 33: S123-S147
- Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N Engl J Med. 2022; 10.1056/NEJMoa2203690https://doi.org/10.1056/NEJMoa2203690
- Examination of low ERBB2 protein expression in breast cancer tissue.JAMA Oncol. Apr 1 2022; 8: 1-4https://doi.org/10.1001/jamaoncol.2021.7239
- Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.J Clin Oncol. 2021; 39 (1021-1021)https://doi.org/10.1200/JCO.2021.39.15_suppl.1021
- Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.Virchows Arch. Aug 16 2022; https://doi.org/10.1007/s00428-022-03378-5
- Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study.J Clin Oncol. Jun 10 2020; 38: 1887-1896https://doi.org/10.1200/jco.19.02318
- Abstract PD6-01: novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients.Cancer Res. 2021; 81PD6-01-PD6-01https://doi.org/10.1158/1538-7445.Sabcs20-pd6-01
- Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.Lab Invest. Oct. 2022; 102: 1101-1108https://doi.org/10.1038/s41374-022-00804-9
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA A Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
Article Info
Publication History
Published online: November 09, 2022
Accepted:
October 14,
2022
Received:
October 12,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Evolution of low HER2 expression between early and advanced-stage breast cancerEuropean Journal of CancerVol. 163
- PreviewLow human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications.
- Full-Text
- Preview
- Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”European Journal of Cancer
- PreviewIn a phase 3, multicentre, open-label, randomised trial, trastuzumab deruxtecan (TD) was superior to the standard of care trastuzumab emtansine in patients with HER2-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane [1]. Then, a phase 3 trial with HER2-low mBC patients (defined as 1+ and 2+ by immunohistochemistry [IHC] or negative by in situ hybridisation [ISH]) who had received previous lines of chemotherapy was performed [2]. In this trial TD resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
- Full-Text
- Preview
